Effects of endothelin receptor antagonists on the plasma immunoreactive endothelin-1 level

Journal of Cardiovascular Pharmacology

Volumn 36, Issue 5 SUPPL. 1, 2000, Pages

  Opgenorth, T J ^a   Wessale, J L ^a   Dixon, D B ^a   Adler, A L ^a   Calzadilla, S V ^a   Padley, R J ^a   Wu Wong, J R ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

A 182086; A 192621; A 216546; ABT 627; Plasma ET 1

Indexed keywords

(2ALPHA,3BETA,4ALPHA) 4 (1,3 BENZODIOXOL 5 YL) 1 [2 (2,6 DIETHYLPHENYL)AMINO] 2 OXOETHYL] 2 (4 PROPOXYPHENYL) 3 PYRROLIDINECARBOXYLIC ACID; A 182086; A 216546; ATRASENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEEDBACK SYSTEM; GENE CONTROL; HUMAN; HUMAN EXPERIMENT; IMMUNOREACTIVITY; MALE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING;

EID: 0033743310     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200036001-00054     Document Type: Article

References (18)

1. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
2. Endothelin: New discoveries and rapid progress in the clinic
3. Signal transduction mechanisms mediating the vascular actions of endothelin
4. Cloning and expression of a cDNA encoding an endothelin receptor
5. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor
6. Biological profile of highly potent novel endothelin antagonists selective for the ET(A) receptor
7. Pharmacological profile of FR139317, a novel, potent, endothelin ET(A) receptor antagonist
8. Pharmacological characterization of A-127722: An orally active and highly potent ET(A)-selective receptor antagonist
9. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist
10. Pharmacology of a non-selective ET(A) and ET(B) receptor antagonist, TAK-044 and the inhibition of myocardial infarct size in rats
11. Pharmacology of A-216546: A highly selective antagonist for the type-A endothelin receptor
12. Pharmacology of A-192621, a nonpeptide, orally active, ET(B) receptor antagonist
13. Characterization of A-182086, a nonpeptide, orally active, nonselective ET antagonist
14. Clearance of circulating endothelin-1 by ET(B) receptors in rats
15. ET(B) receptor and nitric oxide synthase blockade induce BQ-123-sensitive pressor effects in the rabbit
16. Selective ET(A) receptor antagonism reduces neointimal hyperplasia in a porcine coronary stent model
17. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans
18. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects